276 related articles for article (PubMed ID: 3753026)
21. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
23. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
Rossof AH; Coltman CA; Jones SE; Talley RW
Cancer Treat Rep; 1979; 63(9-10):1605-8. PubMed ID: 498159
[TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.
Foss-Abrahamsen A; Lenner P; Hedenus M; Landys K; Noppa H
Cancer Treat Rep; 1987 Dec; 71(12):1209-12. PubMed ID: 3690531
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
26. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
27. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
[TBL] [Abstract][Full Text] [Related]
28. [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Sampi K; Honda T; Hattori M
Gan To Kagaku Ryoho; 1984 May; 11(5):1012-7. PubMed ID: 6202245
[TBL] [Abstract][Full Text] [Related]
29. [A phase II study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) in patients with hematological malignancies. THP Study Group].
Kimura K
Gan To Kagaku Ryoho; 1986 Feb; 13(2):368-75. PubMed ID: 3947112
[TBL] [Abstract][Full Text] [Related]
30. [A phase II study of epirubicin in malignant lymphoma].
Masaoka T; Shibata H; Sampi K; Hirota Y; Yoshida Y; Chiba Y; Shirakawa S; Kobayashi T; Toki H; Tamura K
Gan To Kagaku Ryoho; 1986 Aug; 13(8):2606-11. PubMed ID: 3461747
[TBL] [Abstract][Full Text] [Related]
31. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
[TBL] [Abstract][Full Text] [Related]
33. Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas.
Bajetta E; Buzzoni R; Viviani S; Villani F; Piotti P; Gasparini G; Bonadonna G
Cancer Treat Rep; 1985 Sep; 69(9):965-9. PubMed ID: 3839714
[TBL] [Abstract][Full Text] [Related]
34. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
[TBL] [Abstract][Full Text] [Related]
35. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
36. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
[TBL] [Abstract][Full Text] [Related]
37. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Osborne CK; Drelichman A; Von Hoff DD; Crawford ED
Cancer Treat Rep; 1983 Dec; 67(12):1133-5. PubMed ID: 6652630
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of mitoxantrone in refractory acute leukemia.
Estey EH; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Cancer Treat Rep; 1983 Apr; 67(4):389-90. PubMed ID: 6850655
[TBL] [Abstract][Full Text] [Related]
39. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study.
Weick JK; Jones SE; Ryan DH
Cancer Treat Rep; 1983 May; 67(5):489-92. PubMed ID: 6687839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
